UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Science (American Association for the Advancement of Science), 2019-11, Vol.366 (6468), p.1013-1021

2019

Volltextzugriff (PDF)

The Diversity of Chemoprotective Glucosinolates in Moringaceae (Moringa spp.)

Scientific reports, 2018-05, Vol.8 (1), p.7994-14, Article 7994

2018

Volltextzugriff (PDF)

Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis

Nature communications, 2023-11, Vol.14 (1), p.7427-7427, Article 7427

2023

Volltextzugriff (PDF)

Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma

Translational oncology, 2019-10, Vol.12 (10), p.1314-1322

2019

Volltextzugriff (PDF)

Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

European journal of pharmacology, 2010-01, Vol.626 (2-3), p.193-199

2010

Volltextzugriff (PDF)

Brain Estradiol Content in Newborn Rats: Sex Differences, Regional Heterogeneity, and Possible de Novo Synthesis by the Female Telencephalon

Endocrinology (Philadelphia), 2004-06, Vol.145 (6), p.2906-2917

2004

Volltextzugriff (PDF)

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo

The Journal of pharmacology and experimental therapeutics, 2010-11, Vol.335 (2), p.362

2010

Volltextzugriff (PDF)

The SWELL1 Channel Promotes Ischemic Brain Damage by Mediating Neuronal Swelling and Glutamate Toxicity

Advanced science, 2024-09, Vol.11 (36), p.e2401085-n/a

2024

Volltextzugriff (PDF)

Discovery of a para-Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain

Journal of medicinal chemistry, 2017-09, Vol.60 (18), p.7799-7809

2017

Volltextzugriff (PDF)

Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry

Analytical biochemistry, 2015-04, Vol.474, p.28-34

2015

Volltextzugriff (PDF)

Transitive conformal holonomy groups

Central European journal of mathematics, 2012-10, Vol.10 (5), p.1710-1720

Alt, Jesse

2012

Volltextzugriff (PDF)

Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration

PloS one, 2015-07, Vol.10 (7), p.e0131861-e0131861

2015

Volltextzugriff (PDF)

Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement

Current drug metabolism, 2021-01, Vol.22 (9), p.735-745

2021

Volltextzugriff (PDF)

Inhibition of Glutamate Carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis

Proceedings of the National Academy of Sciences - PNAS, 2012-12, Vol.109 (49), p.20101-20106

2012

Volltextzugriff (PDF)

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

Cell death & disease, 2022-04, Vol.13 (4), p.410-14, Article 410

2022

Volltextzugriff (PDF)

Essential Parabolic Structures and Their Infinitesimal Automorphisms

Symmetry, integrability and geometry, methods and applications, 2011-01, Vol.7, p.039

Alt, Jesse

2011

Volltextzugriff (PDF)

D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II

Pharmaceutics, 2022-09, Vol.14 (10), p.2018

2022

Volltextzugriff (PDF)

Elevated body fat increases amphetamine accumulation in brain: evidence from genetic and diet-induced forms of adiposity

Translational psychiatry, 2021-08, Vol.11 (1), p.427-9, Article 427

2021

Volltextzugriff (PDF)

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

Proceedings of the National Academy of Sciences - PNAS, 2016-09, Vol.113 (36), p.E5328-E5336

2016

Volltextzugriff (PDF)

Discovery of 6‑Diazo-5-oxo‑l‑norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma

Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8621-8633

2016

Volltextzugriff (PDF)

On the twistor space of a quaternionic contact manifold

Journal of geometry and physics, 2011-10, Vol.61 (10), p.1783-1788

Alt, Jesse

2011

Volltextzugriff (PDF)

Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP

Journal of medicinal chemistry, 2022-08, Vol.65 (16), p.11111-11125

2022

Volltextzugriff (PDF)

Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma

Clinical cancer research, 2023-10, Vol.29 (20), p.4209-4218

2023

Volltextzugriff (PDF)

Abstract 3620: Tumor targeted delivery of glutamine antagonist: Use of CES1-/- mice

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3620-3620

2019

Volltextzugriff (PDF)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii279-iii279

2020

Volltextzugriff (PDF)

1 – 25 von 166

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(148)

Publikationsform

Sprache

Englisch
(164)
Deutsch
(2)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

The Diversity of Chemoprotective Glucosinolates in Moringaceae (Moringa spp.)

Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis

Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma

Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function

Brain Estradiol Content in Newborn Rats: Sex Differences, Regional Heterogeneity, and Possible de Novo Synthesis by the Female Telencephalon

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo

The SWELL1 Channel Promotes Ischemic Brain Damage by Mediating Neuronal Swelling and Glutamate Toxicity

Discovery of a para-Acetoxy-benzyl Ester Prodrug of a Hydroxamate-Based Glutamate Carboxypeptidase II Inhibitor as Oral Therapy for Neuropathic Pain

Bioanalysis of 6-diazo-5-oxo-l-norleucine in plasma and brain by ultra-performance liquid chromatography mass spectrometry

Transitive conformal holonomy groups

Selective CNS Uptake of the GCP-II Inhibitor 2-PMPA following Intranasal Administration

Glutamine Antagonist GA-607 Causes a Dramatic Accumulation of FGAR which can be used to Monitor Target Engagement

Inhibition of Glutamate Carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

Essential Parabolic Structures and Their Infinitesimal Automorphisms

D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II

Elevated body fat increases amphetamine accumulation in brain: evidence from genetic and diet-induced forms of adiposity

Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer

Discovery of 6‑Diazo-5-oxo‑l‑norleucine (DON) Prodrugs with Enhanced CSF Delivery in Monkeys: A Potential Treatment for Glioblastoma

On the twistor space of a quaternionic contact manifold

Discovery of Orally Bioavailable and Brain-Penetrable Prodrugs of the Potent nSMase2 Inhibitor DPTIP

Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma

Abstract 3620: Tumor targeted delivery of glutamine antagonist: Use of CES1-/- mice

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT

Suchergebnisse filtern